Aktuelles zur Systemtherapie des metastasierten Nierenzellkarzinoms

The past 5 years were marked by fundamental changes in the systemic therapy of metastatic renal cell carcinoma. Up to the end of the last decade cytokine-based chemotherapy was the only, even if only moderately effective systemic therapy for metastatic renal cell carcinoma. Currently there are five new approved drug releases of so-called targeted substances, which function on a molecular based therapeutic mechanism. Sunitinib (Sutent®) and sorafenib (Nexavar®) as multikinase inhibitors, everolimus (Afinitor®) and temsirolimus (Torisel®) as mTOR inhibitors, and bevacizumab as an antibody against VEGF in combination with interferon-alpha (IFN-α). The following article will give an overview of the currently available substances and critically discuss therapy plans and future trends.